Development of potent and selective tissue transglutaminase inhibitors: their effect on TG2 function and application in pathological conditions

Keyphrases

• Human Umbilical Vein Endothelial Cells (HUVECs) 100%
• Pathological Conditions 100%
• Fibronectin 100%
• Tissue Transglutaminase 100%
• NIH3T3 100%
• Transglutaminase Inhibitors 100%
• Fluorescent Inhibitor 100%
• In Situ 50%
• Cell Surface 50%
• Ionomycin 50%
• Extracellular Matrix 50%
• Cell Motility 50%
• Fluorescently Labeled 50%
• Mouse Model 50%
• Cell Permeable 50%
• Molecular Dynamics 50%
• Syndecan-4 50%
• Collagen Deposition 50%
• Dynamic Method 50%
• Extracellular Space 50%
• Matrigel 50%
• Parallel Reduction 50%
• Docking Dynamics 50%
• Hypertensive Nephrosclerosis 50%
• Cord Formation 50%
• Protein-protein Docking 50%
• Peptidomimetic Inhibitors 50%
• Intracellular Space 50%

Medicine and Dentistry

• Protein Glutamine Gamma Glutamyltransferase 100%
• Fibronectin 100%
• Endothelial Cell 100%
• Umbilical Cord 100%
• Extracellular Matrix 50%
• Cell Surface 50%
• Cell Migration 50%
• Syndecan 4 50%
• Extracellular Space 50%
• Matrigel 50%
• Cell Motility 50%
• Nephrosclerosis 50%
• Protein-Ligand Docking 50%
• Ionomycin 50%
• Peptidomimetics 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Glutamine Gamma Glutamyltransferase 100%
• Fibronectin 100%
• Mouse Model 50%
• Syndecan 4 50%
• Ionomycin 50%
• Protein Ligand 50%
• Matrigel 50%
• Nephrosclerosis 50%
• Peptidomimetics 50%